Catheter Precision, Inc. filings document material events, operating results, shareholder votes, capital-structure matters, and governance disclosures for a NYSE American-listed company. The records include 8-K reports on financial results and business updates tied to the company’s electrophysiology products, including VIVO and LockeT, as well as strategic expansion activity.
VTAK’s proxy and current-report filings also cover stockholder approval matters, common-stock issuance proposals, convertible preferred stock series, promissory note amendments, royalty-right exchanges, related-party transaction disclosures, and other material agreements. These filings frame the company’s public reporting around medical device commercialization, financing arrangements, and corporate governance.
Catheter Precision, Inc. (VTAK) will change its name to Flyte Aviation, Inc. and effect a 1-for-10 reverse stock split at 12:01 a.m. Eastern Time on October 5, 2026. The company said issued and outstanding common shares will decrease from approximately 21,019,874 to approximately 2,101,987; authorized capital stock will remain 500 million common shares and 10 million preferred shares. Trading under the new name and VJET symbol is expected to begin at the October 5 opening.
Stockholders approved a 5,000,000-share increase to the 2023 Equity Incentive Plan reserve and a one-time repricing of options with exercise prices above fair market value to $0.152 per share. After the reverse split, the exercise price of each repriced option will be $1.52 per share; the repricing does not change option share counts, expiration dates or vesting schedules.
Catheter Precision, Inc. approved an amendment to change its name to Flyte Aviation, Inc. and effect a 1-for-10 reverse stock split, expected to become effective at 12:01 a.m. Eastern Time on October 5, 2026. Stockholders approved the split at a special meeting on April 15, 2026, and the Board selected the ratio within the approved range; the name change did not require stockholder approval.
The company intends to file a certificate of amendment. At the effective time, every ten shares issued and outstanding or held in treasury will be combined into one share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive their pro rata portion of net proceeds from the exchange agent’s aggregation and sale of those shares. The split will not change the common stock’s par value or authorized share count, and outstanding equity awards, warrants, and convertible securities will be adjusted proportionately under their terms. Split-adjusted trading is expected to begin on the NYSE American under the name Flyte Aviation, Inc. and ticker VJET at the opening of trading on October 5, 2026.
Catheter Precision, Inc. (VTAK) is asking stockholders at the September 30, 2026 virtual annual meeting to approve several governance and capital-structure changes, alongside routine items. One proposal would reincorporate the company from Delaware to Nevada via a plan of conversion, eliminating Delaware franchise taxes of approximately $200,000 per year and adopting Nevada articles and bylaws that include annual election of all directors and broader director/officer liability protections, while opting out of certain Nevada anti-takeover statutes.
Stockholders are asked to elect David A. Jenkins as the sole Class II director, authorize a discretionary reduction in the conversion price of 9,489.488 Series J preferred shares (held entirely by Mr. Jenkins and his affiliate) from $1.56 down to as low as $0.23 per share, and approve issuance of up to 340,000 common shares upon exercise of Series M warrants granted to Mr. Jenkins and FatBoy Capital, L.P. The Series J amendment could increase the Series J conversion from 6,083,005 to approximately 41,258,209 shares, or about 217% of the 18,972,049 shares outstanding as of the record date.
Additional proposals would increase the 2023 Equity Incentive Plan share reserve by 5,000,000 shares (to 5,067,888 available shares before evergreen adjustments), and authorize a one-time repricing of 507,764 outstanding stock options to fair market value on the approval date, affecting executives, directors and employees. Stockholders are also asked to ratify WithumSmith+Brown, PC as auditor for 2027 and to approve potential adjournment/postponement to solicit additional proxies.
Catheter Precision, Inc. (symbol: VTAK) is the issuer of record for a Form 424B3 filing submitted to the SEC.
Catheter Precision, Inc. (VTAK) is asking stockholders to approve seven items at the 2026 virtual annual meeting. Proposals include electing David A. Jenkins as the sole Class II director and reincorporating the company from Delaware to Nevada, eliminating the classified board so all directors stand for annual elections and reducing Delaware franchise tax costs (currently about $200,000 per year) in favor of Nevada’s lower fee regime.
Stockholders are also asked to approve a Series J preferred stock amendment allowing the board, subject to a floor, to cut the conversion price below $1.56, which could raise the maximum issuable common from Series J to about 41,258,209 shares versus 18,972,049 common shares outstanding as of August 18, 2026. Additional proposals cover authorizing up to 340,000 common shares upon exercise of Series M warrants, adding 5,000,000 shares to the 2023 Equity Incentive Plan, and a one-time repricing of 507,764 underwater options to fair market value (the stock last closed at $0.27 on August 18, 2026). A routine adjournment proposal and statutory dissenters’ rights in connection with the reincorporation are also described.
Catheter Precision, Inc. (VTAK) is reporting that a group of investment entities and individuals, including C/M Capital Master Fund, LP, WVP Emerging Manager Onshore Fund LLC, C/M Capital Partners, LP, Thomas Walsh and Jonathan Juchno, has filed a Schedule 13G regarding its position in the company’s common stock.
The Reporting Persons collectively report beneficial ownership of 1,597,328 shares of common stock, representing 9.99% of the outstanding class. This total includes 159,574 shares of common stock issuable upon conversion of convertible preferred stock held by the funds. Voting and dispositive power over these shares is reported on a shared basis among the group, while Messrs. Walsh and Juchno state that they disclaim beneficial ownership of shares held by the funds.
Catheter Precision, Inc. (VTAK) reported sharply higher revenue but remains loss-making and under a going concern warning. For the six months ended June 30, 2026, total revenues rose to $1.5 million from $0.4 million a year earlier, driven by $0.9 million of new private aviation service revenue from the FLYTE acquisition and growth in cardiac products, including VIVO and LockeT.
Despite this, the company recorded a net loss of $5.0 million and used $5.7 million in operating cash. As of June 30, 2026, cash and cash equivalents were $0.6 million, with a working capital deficit of $10.9 million and an accumulated deficit of $314.5 million. Management states there is substantial doubt about the ability to continue as a going concern and plans to rely on additional equity and debt financings, including a multi-tranche Series C and Series D preferred stock program and related warrant exercises.
Total assets increased to $36.9 million from $15.9 million at year-end 2025, reflecting $13.0 million of goodwill and higher intangible assets from acquiring 100% of private aviation operator FLYTE and its subsidiaries. The business is now managed in two segments: cardiac electrophysiology and private aviation.
Catheter Precision, Inc. completed a private financing on July 30, 2026, issuing 2,821 shares of Series C-4 Convertible Preferred Stock, par value $0.0001 and stated value $1,000 per share, for aggregate gross proceeds of $2,821,000.00. The securities were issued to investors exercising an Additional Investment Right under a March 9, 2026 Securities Purchase Agreement.
The Series C-4 terms are set out in a Certificate of Designation filed July 27, 2026 in Delaware. Dawson James Securities, Inc. acted as placement agent and received customary fees and expenses. The company plans to use net proceeds for working capital, general corporate purposes and to redeem all outstanding Series B Convertible Preferred Stock. The Series C-4 Preferred Stock ranks senior to common stock for dividends and liquidation rights, and any conversion into common stock will dilute existing common shareholders. The issuance relied on exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D, with sales only to accredited investors and subject to transfer restrictions.
Catheter Precision, Inc. filed an amended report to add full-year 2024–2025 financial statements for Fly Flyte, Inc. and Ponderosa Air LLC (together “FLYTE”), which it acquired from Creatd, Inc. on March 9, 2026, plus unaudited pro forma results reflecting this acquisition.
FLYTE operates a private aviation platform. In 2025 it generated $986 thousand of service revenue but recorded a net loss of $4.8 million, negative operating cash flow of $2.3 million, and an accumulated deficit of $17.2 million. Year-end cash was $26 thousand with a working capital deficit of $4.4 million and stockholders’ deficit of $4.7 million.
Auditors raised substantial doubt about FLYTE’s ability to continue as a going concern due to recurring losses, negative cash flows, a leveraged balance sheet, and litigation and lease settlements, despite debt restructurings, gains on extinguishment of debt and leases, and capital contributions from prior owners. After the acquisition, Catheter Precision committed to provide financial support and is pursuing additional financing to fund ongoing operations.
Catheter Precision, Inc. received a Schedule 13G reporting that SEG JETS SPV I, LLC, a Delaware limited liability company, is a significant shareholder. SEG JETS SPV I, LLC reports beneficial ownership of 1,065,620 shares of common stock, with shared voting and dispositive power over all of these shares and no sole power.
This position represents 9.79% of Catheter Precision’s common stock, based on 10,880,868 shares outstanding as verified with the issuer on July 17, 2026. The filing is signed by Joseph Reda, as Manager of SEG JETS SPV I, LLC.